Revenue: As of FY2025 Q1, the actual value is USD 0.EPS: As of FY2025 Q1, the actual value is USD 0.EBIT: As of FY2025 Q1, the actual value is USD -600.03 K.<h3>Segment Revenue</h3><ul><li>No revenue was reported for the three months ended March 31, 2025, and March 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended March 31, 2025, was $600,033, compared to $507,875 for the same period in 2024, representing an increase of 18.15%.</li><li>Operating Expenses: Total operating expenses for the three months ended March 31, 2025, were $580,492, compared to $448,710 for the same period in 2024, an increase of 29.37%.</li><li>General and Administrative Expenses: Increased by 87.89% to $308,851 for the three months ended March 31, 2025, from $164,375 for the same period in 2024.</li><li>Professional Fees: Decreased by 17.26% to $63,035 for the three months ended March 31, 2025, from $76,182 for the same period in 2024.</li><li>Officer’s Salary: Increased by 3.36% to $184,730 for the three months ended March 31, 2025, from $178,718 for the same period in 2024.</li><li>Research and Development: Decreased by 18.89% to $23,876 for the three months ended March 31, 2025, from $29,435 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the three months ended March 31, 2025, net cash used in operations was $434,499, compared to $489,527 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the three months ended March 31, 2025, net cash provided by financing activities was $158,236, compared to a cash outflow of $15,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Investment in Gold Bullion: The net change in unrealized appreciation on investment in gold bullion was $117,488 for the three months ended March 31, 2025, compared to $43,563 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to accelerate and expand commercial scale production of recombinant spider silk, expand research and development, and create a line of recombinant spider silk fashion wear.</li><li>Non-Core Business: The company will consider buying an established revenue-producing company in a compatible business to broaden its financial base and facilitate the commercialization of its products.</li><li>Collaborative Efforts: The company plans to pursue collaborative research and product testing opportunities with companies in biotechnology, materials, textile, and other industries.</li></ul>

Kraig Biocraft Laboratories, Inc. | 10-Q: FY2025 Q1 Revenue: USD 0